Literature DB >> 16868456

No change to HIV-1 latency with valproate therapy.

Alan Steel, Sally Clark, Ian Teo, Sunil Shaunak, Mark Nelson, Brian Gazzard, Peter Kelleher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16868456     DOI： 10.1097/01.aids.0000238421.36313.fa

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  14 in total

1.  Combinatorial latency reactivation for HIV-1 subtypes and variants.

Authors:  John C Burnett; Kwang-Il Lim; Arash Calafi; John J Rossi; David V Schaffer; Adam P Arkin
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

2.  Negative elongation factor (NELF) coordinates RNA polymerase II pausing, premature termination, and chromatin remodeling to regulate HIV transcription.

Authors:  Malini Natarajan; Gillian M Schiralli Lester; Chanhyo Lee; Anamika Missra; Gregory A Wasserman; Martin Steffen; David S Gilmour; Andrew J Henderson
Journal:  J Biol Chem       Date:  2013-07-24       Impact factor: 5.157

Review 3.  HIV-1 transcription and latency: an update.

Authors:  Carine Van Lint; Sophie Bouchat; Alessandro Marcello
Journal:  Retrovirology       Date:  2013-06-26       Impact factor: 4.602

4.  High-throughput screening uncovers a compound that activates latent HIV-1 and acts cooperatively with a histone deacetylase (HDAC) inhibitor.

Authors:  Sofiya Micheva-Viteva; Yoshifumi Kobayashi; Leonard C Edelstein; Annmarie L Pacchia; Hui-Ling Rose Lee; Jason D Graci; Jamie Breslin; Bradley D Phelan; Leia K Miller; Joseph M Colacino; Zhengxian Gu; Yacov Ron; Stuart W Peltz; Joseph P Dougherty
Journal:  J Biol Chem       Date:  2011-04-15       Impact factor: 5.157

Review 5.  From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.

Authors:  Liang Shan; Robert F Siliciano
Journal:  Bioessays       Date:  2013-04-24       Impact factor: 4.345

6.  Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.

Authors:  Sophie Reuse; Miriam Calao; Kabamba Kabeya; Allan Guiguen; Jean-Stéphane Gatot; Vincent Quivy; Caroline Vanhulle; Aurélia Lamine; Dolores Vaira; Dominique Demonte; Valérie Martinelli; Emmanuelle Veithen; Thomas Cherrier; Véronique Avettand; Solène Poutrel; Jacques Piette; Yvan de Launoit; Michel Moutschen; Arsène Burny; Christine Rouzioux; Stéphane De Wit; Georges Herbein; Olivier Rohr; Yves Collette; Olivier Lambotte; Nathan Clumeck; Carine Van Lint
Journal:  PLoS One       Date:  2009-06-30       Impact factor: 3.240

Review 7.  Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies.

Authors:  Laurence Colin; Carine Van Lint
Journal:  Retrovirology       Date:  2009-12-04       Impact factor: 4.602

8.  Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner.

Authors:  Rajeev Mehla; Shalmali Bivalkar-Mehla; Ruonan Zhang; Indhira Handy; Helmut Albrecht; Shailendra Giri; Prakash Nagarkatti; Mitzi Nagarkatti; Ashok Chauhan
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

9.  Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation.

Authors:  Liang Shan; Kai Deng; Neeta S Shroff; Christine M Durand; S Alireza Rabi; Hung-Chih Yang; Hao Zhang; Joseph B Margolick; Joel N Blankson; Robert F Siliciano
Journal:  Immunity       Date:  2012-03-08       Impact factor: 31.745

10.  Mechanisms of HIV Transcriptional Regulation and Their Contribution to Latency.

Authors:  Gillian M Schiralli Lester; Andrew J Henderson
Journal:  Mol Biol Int       Date:  2012-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.